Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.
gamma delta T cell therapiesmedical
Gamma delta T cell therapies are a type of immunotherapy that uses a rare group of immune cells (gamma delta T cells) engineered or expanded to seek out and kill diseased cells such as cancer. Think of them as specially trained search-and-destroy teams that can recognize stressed or abnormal cells in ways standard immune cells cannot. Investors care because these therapies can offer novel, potentially high-impact treatment approaches with significant clinical and commercial upside, but they also carry scientific, safety and regulatory risks that can lead to volatile outcomes.
chimeric antigen receptors (CARs)medical
Chimeric antigen receptors (CARs) are engineered proteins put onto a patient’s immune cells, most often T cells, so those cells can recognize and bind to specific markers on diseased cells and trigger their destruction. They matter to investors because therapies using CARs can become high-value medical products: clinical trial results, regulatory approvals, manufacturing capacity, and commercial uptake of CAR-based treatments can strongly influence a biotech company’s prospects and valuation.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston.
Details of the event are as follows: Date: Tuesday, August 11, 2026 Time: 10:30 a.m. ET
The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at https://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
